Risk Factors for Bleeding in Haemato-oncology Patients-a Nested Case-control Study: The BITE Study Protocol (Bleeding In Thrombocytopenia Explained)

Overview

Journal BMJ Open

Specialty General Medicine

Date 2020 Jul 2

PMID 32606056

Citations 1

Authors

Loes L Cornelissen

Camila Caram-Deelder

Johanna G van der Bom

Rutger A Middelburg

Jaap Jan Zwaginga

Affiliations

Soon will be listed here.

Abstract

Introduction: Haemato-oncological patients often receive platelet count driven prophylactic platelet transfusions to prevent bleeding. However, many prophylactically transfused patients still bleed. More knowledge on risk factors for bleeding is therefore needed. This will enable identification of bleeding risk profiles on which future transfusion policy can be optimised. The present BITE study (Bleeding In Thrombocytopenia Explained) aims to identify clinical conditions and biomarkers that are associated with clinically relevant bleeding events.

Methods And Analysis: A matched case-control study nested in a cohort of haemato-oncological patients in the Netherlands. We collect a limited number of variables from all eligible patients, who together form the source population. These patients are followed for the occurrence of clinically relevant bleeding. Consenting patients of the source population form the cohort. Cases from the cohort are frequency matched to selected control patients for the nested case-control study. Of both case and control patients more detailed clinical data is collected.

Study Population: Adult haemato-oncological patients, who are admitted for intensive chemotherapeutic treatment or stem cell transplantation, or who received such treatments in the past and are readmitted for disease or treatment-related adverse events.

Statistical Analysis: Bleeding incidences will be calculated for the total source population, as well as for different subgroups. The association between potential risk factors and the occurrence of bleeding will be analysed using conditional logistic regression, to account for matching of case and control patients.

Ethics And Dissemination: The study was approved by the Medical Research Ethics Committee Leiden Den Haag and Delft, and the Radboudumc Committee on Research Involving Human Subjects. Approval in seven other centres is foreseen. Patients will be asked for written informed consent and data is coded before analyses, according to Dutch privacy law. Results will be published in peer-reviewed journals.

Trial Registration Number: NL62499.058.17. NCT03505086; Pre-results.

Citing Articles

Platelet transfusion and tranexamic acid to prevent bleeding in outpatients with a hematological disease: A Dutch nationwide survey.

Cornelissen L, Caram-Deelder C, Meier R, Zwaginga J, Evers D Eur J Haematol. 2020; 106(3):362-370.

PMID: 33226659 PMC: 7898625. DOI: 10.1111/ejh.13555.

References

Miller A, Hoogstraten B, STAQUET M, Winkler A . Reporting results of cancer treatment. Cancer. 1981; 47(1):207-14. DOI: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. View

Morito T, Ando M, Kobayashi T, Kakihana K, Ohashi K, Akiyama H . New-onset microalbuminuria following allogeneic myeloablative SCT is a sign of near-term decrease in renal function. Bone Marrow Transplant. 2013; 48(7):972-6. DOI: 10.1038/bmt.2012.271. View

Parekh R, Kao W, Meoni L, Ipp E, Kimmel P, La Page J . Reliability of urinary albumin, total protein, and creatinine assays after prolonged storage: the Family Investigation of Nephropathy and Diabetes. Clin J Am Soc Nephrol. 2007; 2(6):1156-62. DOI: 10.2215/CJN.01030207. View

De Cuyper I, Meinders M, van de Vijver E, de Korte D, Porcelijn L, de Haas M . A novel flow cytometry-based platelet aggregation assay. Blood. 2013; 121(10):e70-80. DOI: 10.1182/blood-2012-06-437723. View

Kitchens C, WEISS L . Ultrastructural changes of endothelium associated with thrombocytopenia. Blood. 1975; 46(4):567-78. View

Ypma P, Kerkhoffs J, van Hilten J, Middelburg R, Coccoris M, Zwaginga J . The observation of bleeding complications in haemato-oncological patients: stringent watching, relevant reporting. Transfus Med. 2012; 22(6):426-31. DOI: 10.1111/j.1365-3148.2012.01193.x. View

Miettinen O . Estimability and estimation in case-referent studies. Am J Epidemiol. 1976; 103(2):226-35. DOI: 10.1093/oxfordjournals.aje.a112220. View

Estcourt L, Stanworth S, Murphy M . Platelet transfusions for patients with haematological malignancies: who needs them?. Br J Haematol. 2011; 154(4):425-40. DOI: 10.1111/j.1365-2141.2010.08483.x. View

Woywodt A, Scheer J, Hambach L, Buchholz S, Ganser A, Haller H . Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem cell transplantation. Blood. 2004; 103(9):3603-5. DOI: 10.1182/blood-2003-10-3479. View

10.

Stanworth S, Estcourt L, Powter G, Kahan B, Dyer C, Choo L . A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 2013; 368(19):1771-80. DOI: 10.1056/NEJMoa1212772. View

11.

Kaatz S, Ahmad D, Spyropoulos A, Schulman S . Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2016; 13(11):2119-26. DOI: 10.1111/jth.13140. View

12.

Deforest M, Grabell J, Albert S, Young J, Tuttle A, Hopman W . Generation and optimization of the self-administered bleeding assessment tool and its validation as a screening test for von Willebrand disease. Haemophilia. 2015; 21(5):e384-8. PMC: 4696512. DOI: 10.1111/hae.12747. View

13.

Grimes D, Schulz K . Compared to what? Finding controls for case-control studies. Lancet. 2005; 365(9468):1429-33. DOI: 10.1016/S0140-6736(05)66379-9. View

14.

Rodeghiero F, Tosetto A, Abshire T, Arnold D, Coller B, James P . ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010; 8(9):2063-5. DOI: 10.1111/j.1538-7836.2010.03975.x. View

15.

Estcourt L, Stanworth S, Doree C, Hopewell S, Murphy M, Tinmouth A . Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev. 2012; (5):CD004269. DOI: 10.1002/14651858.CD004269.pub3. View

16.

Larsen A, Leinoe E, Johansson P, Birgens H, Ostrowski S . High syndecan-1 levels in acute myeloid leukemia are associated with bleeding, thrombocytopathy, endothelial cell damage, and leukocytosis. Leuk Res. 2013; 37(7):777-83. DOI: 10.1016/j.leukres.2013.02.015. View

17.

Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M . Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet. 2012; 380(9850):1309-16. DOI: 10.1016/S0140-6736(12)60689-8. View

18.

Stanworth S, Hudson C, Estcourt L, Johnson R, Wood E . Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica. 2015; 100(6):740-7. PMC: 4450619. DOI: 10.3324/haematol.2014.118075. View

19.

Stanworth S, Estcourt L, Llewelyn C, Murphy M, Wood E . Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion. 2014; 54(10):2385-93. DOI: 10.1111/trf.12646. View

20.

Estcourt L, Birchall J, Allard S, Bassey S, Hersey P, Kerr J . Guidelines for the use of platelet transfusions. Br J Haematol. 2016; 176(3):365-394. DOI: 10.1111/bjh.14423. View